Effects of xenobiotics on CYP1 enzyme-mediated biotransformation and bioactivation of estradiol.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanistic pathways and preclinical structure-activity relationships without new empirical human data.
PubMed 36823774 · doi:10.1080/03602532.2023.2177671
What was done
Narrative review summarizing published literature on natural and synthetic xenobiotics that inhibit or induce cytochrome P450 family 1 (CYP1) enzymes (CYP1A1, CYP1A2, CYP1B1) involved in estradiol biotransformation, focusing on chemical categories and structure-activity relationships.
What was found
The abstract reports no quantitative experimental numbers. It describes the biochemical pathway wherein CYP1A1 and CYP1A2 catalyze the conversion of estradiol to non-toxic 2-hydroxyestradiol, whereas CYP1B1 catalyzes conversion to genotoxic 4-hydroxyestradiol, which forms reactive oxygen species and quinone intermediates that induce DNA damage. Thousands of natural and synthetic planar polycyclic compounds modulate these enzymes with selectivity determined by structural motifs.
Why it matters
Clarifying how xenobiotics alter the enzymatic balance between protective and genotoxic estradiol metabolites outlines potential biochemical mechanisms underlying environmental and chemical contributions to estrogen-associated cancer risk.
Limits
This is a narrative review providing mechanistic reasoning without new clinical or epidemiological data. The abstract presents no quantitative effect sizes, kinetic parameters, or systematic search details.
Cited by
- supports The 4-hydroxyestrogen (4-OH) metabolic pathway is carcinogenic and associated with cancer development.